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ABSTRACT
Minor histocompatibility antigens (miHA) are responsible for the occurrence of graft-versus-host disease in
the setting of a major histocompatibility complex matched sibling allogeneic stem cell transplantation. These
miHA are peptide fragments that are associated with major histocompatibility complex class I or class II
antigens. Elegant experiments have led to the molecular characterization of these antigens. Efforts to prevent
graft-versus-host disease could be targeted through this pathway by matching for these miHA or by preventing
antigen recognition. Alternatively, these miHA could be exploited as targets for a more potent graft-versus-
malignancy effect. This area of miHA promises to continue to be an exciting area of continued research.
© 2004 American Society for Blood and Marrow Transplantation
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GNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (SCT) is the treatment of choice for a variety of
alignant and nonmalignant disorders [1]. Graft-ver-
us-host disease (GVHD) is a major cause of morbid-
ty and mortality even when transplants are between
iblings who are matched at the major histocompati-
ility complex (MHC) for HLAs [2-7]. GVHD in its
cute or chronic form can signiﬁcantly affect the treat-
ent outcome and the quality of life of long-term
urvivors [4-7].
GVHD occurs when transplanted donor-derived
cells recognize and react to histoincompatible an-
igens expressed on recipient cells. GVHD is the di-
ect result of one of the principal functions of the
mmune system, ie, the distinction of self from non-
elf, or possibly is a result of some danger signal. Final
onsequences of the GVHD process are host tissue
njuries to varying degrees of clinical severity [3,7].
he fundamentals of GVHD include the transfer of
enetically disparate donor-derived T cells into a host
ncapable of rejecting them [3,8]. Three factors are
equired for the occurrence of a graft-versus-host
GVH) reaction, as outlined by Billingham [8] in his
istorical Harvey lecture in 1966. The ﬁrst require- m
B&MTent for a GVH reaction is that the graft must con-
ain a sufﬁcient number of immunologically compe-
ent cells. The second requirement is that the host
hould have important transplantation isoantigens
hat are lacking in the graft. Hence, the host seems
oreign to the graft and is capable of stimulating donor
ells. The third requirement is that the host immune
ystem must be incapable of mounting an effective
mmune response against the graft, at least for a suf-
cient time for the latter to manifest its immunologic
ompetence.
Speciﬁc host cells are recognized as foreign by the
lloreactive donor-derived T lymphocytes. Clinical
anifestations of GVHD depend on the degree of
onor-host histocompatibility and graft alloreactivity
o major host antigens. The aim of this review is to
utline the important biological basis of GVHD, with
mphasis on minor histocompatibility antigens
miHA) and how these antigens may be explored to
mprove outcome in patients.
RAFT-VERSUS-HOST DISEASE
GVHD is one of the major risk factors, if not the
ajor risk factor, after allogeneic SCT. In this setting,
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2t is not difﬁcult to understand that GVHD can occur
s immunocompetent cells are transferred into an im-
unodeﬁcient host. This process of immune recogni-
ion is similar in many ways to organ rejection, al-
hough in the case of SCT, it is the donor that is
ejecting the host. However, in the organ-rejection
nalogy, the donor and recipient are commonly mis-
atched at the MHC, and, therefore, the HLAs are
ifferent. These antigens are able to trigger T-cell
esponses, and this leads to graft rejection. Other
ntigens, such as ABO blood groups and related anti-
ens, can also provoke antibody-mediated rejection,
ut these are usually excluded from the usual tissue
istocompatibility deﬁnition because they do not elicit
-cell responses. In the case of an HLA-matched
ibling pair, the HLA antigens are genotypically iden-
ical, and yet GVHD occurs frequently and can be
atal at times. In this case, T-cell recognition cannot
ccur through a mismatch at the HLA molecule per se
ecause they are identical.
An explanation for GVHD occurring in the pres-
nce of identical HLA molecules came from studies of
ongenic mice. These are animals that are bred to be
dentical at the MHC locus but that are disparate in
he other areas of their genome. Studies in these
nimals led to the conclusion that there were other
ntigens that were important in triggering graft rejec-
ion, and these became known as miHAs. It is some-
hat of a misnomer to call these antigens minor,
ecause severe GVHD can occur that leads to death.
search for structural antigens similar to those of the
HC was not fruitful, and these antigens remained
lusive for several decades. However, it was clear from
igure 1. Map of the HLA region. The gene map of the HLA
egion spans approximately 4  106 nucleotides and is divided into
regions. In general, the class I molecules interact with CD8 cells
nd present endogenous antigens, whereas the class II molecules
nteract with CD4 cells and present exogenous antigens. Within
he class II region also lie the transporter proteins, which are
mportant for antigen presentation. The class III region encodes for
he heat shock proteins, tumor necrosis factor, and complement
roteins.arly murine models that mature donor T cells, of w
16oth CD4 and CD8 subsets, could mediate lethal
VHD directed to miHAs [9,10].
ENETIC BASIS OF ACUTE GVHD
Before we discuss the importance of miHA, it is
elpful to brieﬂy review the MHC because these HLA
olecules underlie the recognition of antigens by T
ells. The MHC is highly polymorphic from individ-
al to individual and segregates in families in a Men-
elian codominant fashion. Major histocompatibility
ntigens encoded by the MHC genetic loci have a
ajor effect on transplantation and on the biological
rogress of GVHD [3,11]. MHC is a closely linked
ighly polymorphic multigene and multiallelic com-
lex that plays a central role in both cell-mediated and
umoral immune responses. MHC genes are found in
ll mammals and vertebrates and consist of a number
f closely linked genetic loci that function as a system
Figure 1). These loci are located on the short arm of
hromosome 6 at the p21 position in humans and
ncodes HLA [12]. Two of the most important dis-
inct classes of cell surface molecules are the class I
nd II molecules (Figure 2). There are several differ-
nt types of class I and II molecules. Class I molecules
HLA-A, -B, and -C) are expressed on the surfaces of
irtually all nucleated cells at varying densities [3].
LA class II molecules (HLA-DR, -DQ, and -DP)
re expressed primarily on cells of the immune re-
igure 2. MHC class I molecule. Class I MHC is a membrane-
panning molecule composed of 2 proteins. It is divided into 3
lobular domains: -1, -2, and -3; -1 is closest to the amino
erminus, and -3 is closest to the membrane. The bound peptide
its within the groove created by the 2  helices. The MHC class II
olecule is similarly composed of 2 membrane-spanning proteins
nd is not associated with -2 microglobulin. Instead, there are 2
lobular domains termed (1) -1 and -2 and (2) -1 and -2. The
regions farthest from the membrane are -1 and -1. The 2 chains
ssociate without covalent bonds. The bound peptide likewise sits
ithin the groove.
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Bponse system, particularly B lymphocytes and anti-
en-presenting cells (APC) such as monocytes, den-
ritic cells, and macrophages [3]. However, cytokines
ecreted by lymphocytes and monocytes during im-
une activation may cause dramatic increases in class
I HLA antigen expression, even on cell types that
ormally have little or no surface expression. HLA-A,
B, and -DR molecules seem to be the most important
oci for determining whether transplanted cells initiate
GVH reaction [3,12-14]. Matching SCT recipients
ith sibling donors sharing identical HLA molecules
igniﬁcantly improved engraftment kinetics and de-
reased GVHD severity [1,15,16]. CD4 and CD8
cells recognize foreign antigens via their presenta-
ion by class II and class I HLAmolecules, respectively
Figure 3). The structure of the MHC class II mole-
ule is similar to that of the class I molecule [17].
Although there is no doubt that HLA matching is
mportant and that miHAs are also important, GVHD
s not simply the result of mismatching. Although it is
ikely that a GVH reaction always occurs in the case of
ismatching, whether the disease itself occurs is re-
ated to many other factors, such as the preparatory
egimen (the type and dose of radiation, chemother-
py, or both), the amount of prior therapy, past cyto-
egalovirus exposure, and the GVHD prophylaxis
egimen [7]. Moreover, the contribution of selected
igure 3. Antigen-presenting cell (APC) and T-cell interaction.
he APC presents the peptide antigen (in this case, a minor histo-
ompatibility antigen) to the T-cell receptor. The agretope inter-
cts with the MHC molecule while the epitope interacts with the
-cell receptor.ytokines to this disease process has been elucidated p
B&MTecently [5,18]. Other factors, such as the ability to
resent the speciﬁc antigen or the ability of an acti-
ated T cell to trafﬁc and home to a particular tissue,
ay also play an important role in whether GVHD
ltimately occurs [19]. Although miHA is critical to
he induction of GVHD, other factors contribute to
ltimately determine whether the disease occurs. This
eview will primarily discuss the initial antigen recog-
ition and downstream events. However, it is impor-
ant to remember that there are cellular and cytokine
actors that are in a balance between the induction of
VHD from the activated T cells and the control of
VHD through regulatory T cells [20,21].
NTIGEN PRESENTATION
HLA molecules provide the crucial surface upon
hich T-cell receptors (TCRs) recognize foreign
nonself) antigens. These antigens come from proteins
hat are broken down in to peptide fragments and
resented by class I or II molecules on the surface of
he APC. Proteins routinely undergo processing into
maller peptide fragments within the cell; the mecha-
ism differs with the actual location of the proteins. In
he case of HLA class I–restricted antigens, the intra-
ellular protease machinery (proteasome) must ﬁrst
egrade cytoplasmic proteins into fragments, usually
f 8 to 11 amino acids. These peptides are then trans-
orted to the endosome compartment by transporter
olecules (transporter in antigen processing). In the
ndoplasmic reticulum, the peptides bind to available
lass I molecules, and the assembled complexes are
ransported to the cell surface [22].
Class II molecules function primarily to present
eptides stemming from the external milieu of the
ell. Class II molecules present antigenic fragments (in
he form of linear peptides) to the CD4 inducer (or
elper) T cells, whereas class I molecules function at
he effector phase of immunity by presenting antigens
o CD8 T cells, which generally have cytotoxic func-
ion. This process of antigen presentation consists of
he binding of a single TCR to a complex on the
urface of an APC that consists of the MHC molecule
nd a peptide fragment derived from the foreign an-
igen. In an allogeneic SCT, the principal antigenic
argets of the T cells of the graft are the host HLA
olecules if the patient and donor HLA molecules
iffer. However, for grafts matched at the HLA, the
ifferent peptides sitting in the binding groove of the
LA molecule, termed miHA, seem to underlie the
evelopment of GVHD [3].
Minor differences in these peptide sequences as
ompared with the native peptide (such as substitution
f 1 amino acid) can also have profound consequences
n the outcome of TCR/peptide/MHC interactions,
ossibly resulting in partial activation [22,23]. TCR
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2nteractions therefore do not simply activate or disable
T cell; rather, in response to subtle variations of
eptide sequences, this engagement may cause a mul-
itude of responses that range from profoundly helpful
o deleterious. These peptide differences may cause
hanges in the binding of the TCR or alter its binding
o the HLA molecule. Moreover, peptide differences
ay have a signiﬁcant effect on how the peptide is
nitially processed through the proteosome complex.
hus, these differences in processing may account for
ntigen presentation being possible in the recipient
ut not in the donor. In such a case, donor T cells may
ot be educated to such a particular antigen as “self ”
nd, therefore, can mount an immune response
gainst such an antigen present on the recipient cells.
everal miHAs seem to function in this manner [24-
6]. Small changes in peptides may shift a vigorous
roliferative response to the induction of an anergic
tate (or vice versa). These changes have been referred
o as altered peptide ligands [27].
INOR HISTOCOMPATIBILITY ANTIGENS
When the SCT donor and the recipient are MHC
dentical, alloreactivity can occur through the TCR
ecognition by donor T cells of different host-derived
eptides bound to the self-same MHC molecules on
ost APCs. These are the so-called miHAs and are
ikely derived from a wide range of endogenous pro-
eins (eg, transferrin and myoglobin) that may possess
enetic polymorphisms between individuals [28]. Be-
ause T cells do not recognize antigens alone, but in
onjunction with the MHC (usually self) on an APC
29], miHAs are bound and presented in the clefts of
he MHC molecules, and these complexes are then
ecognized by TCRs of individual speciﬁc donor T
ells. Alloreactivity is thus the combined effect of
ecognition by numerous donor T cells of different
onself host peptides presented by MHC molecules
n APCs [30,31]. Presentation of miHA (host peptide)
y the MHC class II molecules leads to activation of
onor CD4 T cells, and, likewise, presentation by
lass I molecules induces responses of CD8 T cells.
VHD, and the immunopathology associated with it,
evelops as a consequence of these donor T-cell re-
ponses to the host miHA.
The other variable in the induction and develop-
ent of GVHD is the target or tissue distribution of
he miHA. Some are distributed broadly throughout
omatic tissues, whereas others seem to be lineage
estricted. These differences may correlate with the
ntensity and localization of the immunopathology of
VHD in a given transplantation setting.
urine Studies
Previous experimental data have demonstrated
hat miHAs are peptides, and one could use this f
18nowledge to attempt to prevent GVHD. Unrelated
eptides (ie, not native to the host and nonimmuno-
enic) with a strong binding afﬁnity to MHC class II
olecules could successfully inhibit a secondary mixed
ymphocyte reaction in vitro and prevent GVHD in
ivo. The administration of speciﬁc peptides with
igh-afﬁnity binding for their respective MHC class II
olecules was capable of preventing GVHD in 2
eparate murine models [32]. In both murine models,
he mechanism of prevention was found to be MHC
ssociated, because nonbinding peptides had no clin-
cal effects. However, this approach has been limited
y the need for allele speciﬁcity of the inhibitor pep-
ides and by the difﬁculty of achieving sustained tissue
evels of such low-molecular-weight peptides over a
rolonged period after injection.
One possibility for overcoming the concerns ex-
ressed previously was to use a larger synthetic
olypeptide with promiscuous binding to MHC class
I molecules [33,34]. The molecule chosen is a ran-
om synthetic amino acid polymer composed of gly-
ine, alanine, lysine, and tyrosine, which we have
ermed GLAT (also known commercially as Copax-
ne; Teva Pharmaceutical Industries, Ltd., Jerusalem,
srael); it had been demonstrated to be effective in the
revention and treatment of experimental allergic en-
ephalomyelitis. We next tested this polymer for its
tility in the prevention of acute GVHD. GLAT was
ffective in the prevention of proliferative responses in
itro and was able to prevent GVHD in vivo in a
urine model of bone marrow transplantation across
inor antigenic differences [35]. These murine stud-
es led to a phase I clinical trial that used this molecule
n the therapy of steroid-refractory GVHD (data are
resented below).
haracterization of Minor Antigens
The miHAs have been identiﬁed by cloning T
ells from recipients of allogeneic SCT who devel-
ped GVHD. These cloned T cells allow for the
haracterization of HLA class I–restricted miHAs.
he peptides have been primarily characterized
hrough elution from puriﬁed class I molecules, which
re then fractionated by high-performance liquid
hromatography and analyzed by mass spectroscopy
24-26,36]. The miHAs termed HA-1, HA-2, and
A-8 and male-speciﬁc miHA have been character-
zed in this manner. Another elegant method to char-
cterize the miHA termed HB-1 was through com-
lementary DNA (cDNA) expression cloning. In
hese experiments, messenger RNA was isolated from
iHA-positive Epstein-Barr virus transformed lym-
hocytes, and a cDNA library was constructed [37,38].
hese cDNAs were then co-transfected with the
DNA of the restricting HLA molecule and trans-
ected into COS-1 cells. The readout for the expres-
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Bion of the antigen was through the ability to stimulate
speciﬁc cytotoxic T lymphocyte (CTL) to produce
umor necrosis factor-.
The search for class II binding miHAs has been
ore difﬁcult because the processing involves several
ther molecules, such as the invariant chain, which is
mportant for the stability of the HLA molecule and
he transport of the peptide, and HLA-DM, which is
mportant for proper peptide processing. Recently,
he ﬁrst class II–restricted miHA was identiﬁed
39,40]. In human studies, the Y-speciﬁc genes were
laced into a retrovirus and transduced into female
LA-DQ5 Epstein-Barr virus transformed lympho-
ytes. A CTL speciﬁc for the HLA-DQ5 HY was then
sed to lyse the transfected cells. Lysis occurred from
ragments of the DBY protein, which was used to
ocalize the miHA. Another method that has been
uccessful in the search for class II miHAs is to screen
recombinant bacterial library or COS cells retrovi-
ally transduced with HLA-DM and Ii. In this case,
he CTL-speciﬁc cell line is again used to screen those
lones [41]. However, responses to miHA are likely to
e heterogeneous and will vary depending on the
enetic background of the individual [42-44].
It is possible that a unique minor antigen, such as
ne directed against hematopoietic cells, would not
ead to GVHD because the expression of restricted
ntigens to the hematopoietic stem cells should not
ause GVHD of the skin or liver. Although it is clear
hat reactivity to a restricted miHA must be limited to
he tissue where the MHC class I are expressed, recent
tudies in a murine model for MHC disparities dem-
nstrated that the toxicity may be broader than the
imited antigen-expressing target [18]. In this murine
tudy, T-cell responses directed speciﬁcally at recipi-
nt dendritic cell miHAs were able to induce acute
VHD in the absence of broad T-cell responses di-
ected against the target tissues of GVHD, such as the
iver. The local inﬂammatory response results in an
xcess of cytokine production that is sufﬁcient to cause
amage to the organ. However, in models in which
VHD was directed only against miHA, expression
y nonhematopoietic tissues seemed required and may
e related to the ability of APCs to sustain T-cell
timulation and to the importance of direct target cell
ytolysis for tissue damage [45,46].
linical Data
Because the manner in which a particular protein
s processed is dependent on genes outside of the
HC, 2 siblings, despite having identical MHC mol-
cules, will have different peptides in the MHC
roove. The identiﬁcation of the particular peptides
esponsible for GVHD has been an area of intense
esearch. The earliest and most logical minor antigen
as derived from studies of sex-disparate SCT. In this I
B&MTase, the male-speciﬁc HY antigens have been shown
o play an important role. These male-speciﬁc anti-
ens have been characterized recently [39,47-50]. It is
nteresting that these antigens seem to play an impor-
ant role in the ability of a donor to reject the graft,
ut there are only limited data to suggest that these
ntigens play a role in GVHD, perhaps because of
here these antigens are expressed. This is also true in
urine models, in which many immunodominant mi-
As, deﬁned by CTL activity or by skin graft rejec-
ion, do not seem to correlate with GVHD potential
43,51,52].
Many potential miHA antigens exist in humans,
ut the actual number that may cause GVHD is prob-
bly limited. One such antigen, the HA-2 peptide, has
een found to be a member of the class I myosin
amily [53,54]. In one clinical study, 5 miHA antigens
HA-1, -2, -3, -4, and -5) recognized by T cells in
ssociation with HLA-A1 and -A2 were studied in
ecipients of bone marrow transplants [55]. Mis-
atching of HA-1 alone was signiﬁcantly correlated
ith acute GVHD (greater than grade II; P  .02),
nd mismatching at HA-1, -2, -4, and -5 was also
ssociated with GVHD (P  .006). Acute GVHD
eveloped in all cases in which an HA-1–positive pa-
ient received an HA-1–negative graft. HA-1 is also
fﬁcient in inducing antigen-speciﬁc CTLs [56]. An-
ther possible miHA is the polymorphic residues of
D31. An initial study demonstrated that allelic dif-
erences in this molecule were associated with the
evelopment of GVHD [57]. These ﬁndings have
emained somewhat controversial because several, but
ot all, have conﬁrmed that allelic differences are
mportant in the etiology of GVHD [58,59].
XPLOITING miHA DIFFERENCES
As mentioned previously, miHAs have been asso-
iated with known graft rejection, especially in the
ase of HY antigen. Cloning T cells responsible for
raft rejection led to the discovery of male-speciﬁc
nd other miHAs [50,60,61]. One possible method to
xploit these miHAs is to use the miHAs of the ma-
ignant cells as targets for T-cell responses. Thus, in
he setting of HLA-matched SCT, the responses
gainst miHA of the leukemia cells could be boosted
s a method to improve the graft-versus-leukemia
GVL) effect. Laboratory studies have demonstrated
hat these male-speciﬁc antigens, as well as HA-1
hrough HA-5, HA-8, and HB-1, can be recognized
n leukemic precursors by the speciﬁc T-cell clones
25,62,63]. These approaches of optimizing GVL re-
ponses may be even more important in the setting of
onablative SCT, where the antileukemic effect of the
onor cells is the critical component of the procedure.
n these cases, the use of donor lymphocyte infusions,
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2f directed against the speciﬁc miHA, could result in
mportant tumor control without excessive toxicity.
or example, HA-1 and HA-2 were known to contrib-
te to the occurrence of GVHD, and T cells speciﬁc
gainst these antigens were known to kill HA-1– and
A-2–positive leukemic cells [62]. In a series of ele-
ant experiments, donors and recipients who were
ismatched at these 2 miHAs were studied for the
ppearance of T cells that were speciﬁc for the miHA
y using tetramers of the HLA/peptide complexes. In
hese studies, the disappearance of the malignant cells
oincided with a dramatic increase in the HA-1– and
A-2–speciﬁc T cells [64]. In another case, the emer-
ence of HY-speciﬁc T cells was also associated with
he development of acute GVHD. This recognition
rocess can be found in CD4 cells as well. In one
ase of graft rejection in a female patient with aplastic
nemia who received a stem cell graft from her
rother, HY-speciﬁc MHC class II–restricted CD4
cells were isolated from the recipient [65]. These
-helper cells mature dendritic cells and can enhance
he expansion of MHC class I–restricted CD8 T
ells. This mechanism therefore completes the im-
une response cycle, with interactions between
D4 and CD8 cells and dendritic cells leading to a
iHA-speciﬁc response.
The use of tetramers to detect these cells also
llowed for their isolation. Once isolated, these cells
an be expanded in vitro and tested for their ability to
yse speciﬁcally leukemic targets, as has been done for
VHD patients [66]. These T-cell clones could then
e used for donor leucocyte infusion, resulting in
peciﬁc tumor responses. Although there could still be
risk of GVHD because of the cytokine production
esulting from activation of these cells, the overall
ncidence should be lower given the more restricted
TL targets. Thus, adoptive transfer of tumor-spe-
iﬁc T cells could overcome the delay in the host of
ounting a speciﬁc, effective immune response, espe-
ially in those tumors in which the growth rate is
apid. Moreover, these miHAs could be loaded onto
endritic cells, and the recipient could be speciﬁcally
mmunized against these miHAs as a method to en-
ance the GVL effect. Another method to generate
iHA-speciﬁc, leukemia-reactive CTLs has been to
se chronic myeloid leukemia cells as stimulators in
he presence of -interferon [67].
Not all targets of GVL are miHAs. Other tissue-
peciﬁc antigens can also be useful targets for the
VL effect. For example, proteinase-3 and other pro-
eins that are speciﬁc in the malignant myeloid cells
re clear targets for CTLs [68]. PR-1 peptide, which is
erived from proteinase-3, is the target for these T
ells. Patients who achieve a complete remission have
he concurrent appearance of these cells speciﬁc for
R-1 in their circulation. Moreover, inoculation with r
20roteinase-3 peptides resulted in detectable T cells
peciﬁc for this antigen and in clinical remissions [69].
LINICAL TRIAL USING ANTIGEN-PRESENTATION
LOCKADE
As previously mentioned, murine studies with
LAT resulted in the binding of this random polymer
o the MHC molecule and prevented the recognition
f T cells of the miHA differences between 2 congenic
trains of mice. In an effort to exploit these ﬁnding in
he mouse, we have tested this molecule for its utility
n humans. We have conducted a clinical phase I trial
y using this synthetic polymer, GLAT, for the treat-
ent of steroid-refractory acute GVHD. Twelve pa-
ients received GLAT as therapy for acute GVHD at
tanford or Duke University. Five patients had 1 prior
cute GVHD therapy, and 7 had 2 to 5 prior acute
VHD therapies. All patients had experienced treat-
ent failure with 4 or more days of corticosteroid
reatment at 2 mg/kg/d (9 patients) or 1 mg/kg/d (3
atients) with a calcineurin inhibitor. Five patients
ad grade III skin-only GVHD. All 5 patients re-
ponded: 3 with complete resolution of GVHD (al-
hough 1 received concomitant photopheresis), 1 with
sustained partial remission, and 1 with a transient
-week partial remission. Seven patients had overall
rade IV GVHD that involved the skin, gut, or liver.
ive of these 7 patients had responses: 3 with complete
esolution and 2 with transient resolution of 30 and 50
ays. Two patients had no response. Eleven patients
ied. Four patients died of progressive GVHD with or
ithout infectious complications (2 cytomegalovirus
nd 1 aspergillus). One patient with complete resolu-
ion died with probable pulmonary chronic GVHD.
he remaining patients died of relapsed malignancy
n  3), bacterial infection (n  2), or interstitial
neumonia (n  1). One patient was alive 10 months
fter transplantation without active GVHD. Dose es-
alation of GLAT from 20 to 80 mg/d was achieved
ithout dose-limiting toxicities. In summary, GLAT
as efﬁcacy in patients with steroid-refractory GVHD
f the skin, gut, and liver, with a sustained response in
of 12 patients and without identiﬁable toxicity. Un-
ortunately, the prognosis of patients with steroid-
efractory acute GVHD is guarded. In this small
hase I trial, GLAT did not improve the expected
oor outcome of this patient population. However,
hese preliminary data may support the use of GLAT
arlier in the course of prevention of acute GVHD at
time where blocking antigen presentation through
iHA may be more effective.
ONCLUSION
The occurrence of GVHD remains a major bar-
ier to effective SCT and limits its use in many dis-
e
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Bases. The antigens responsible for acute GVHD in an
LA-matched SCT are miHAs. These miHAs are
eptides from endogenous proteins that are expressed
n the host APCs. These peptide differences between
he host and the donor lead to donor CTLs reacting
gainst the host antigens, which leads to the resulting
amage to the target tissues. One potential for pre-
enting GVHD would be to interfere with the miHA
resentation, thereby abrogating the initial step to-
ard T-cell activation. However, these miHAs can be
xploited when their expression is restricted, for ex-
mple, to the malignant leukemic cells. The ability to
enerate miHA-speciﬁc T-cell clones and to isolate
nd expand these clones against the malignant cells
ould result in a more effective donor leucocyte in-
usion. Moreover, vaccine strategies against these
iHAs could also improve control of the malignant
isease. The technology to identify, isolate, and ex-
and such cells is now available. Clinical trials using
his approach of adoptive T-cell therapy or target
mmunization to such antigens are in their initial
hases but promise to be an exciting area of further
esearch.
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